VEGF inhibitors

VEGF inhibitors are drugs that block vascular endothelial growth factor, a signaling protein tumors use to grow new blood vessels. By cutting off this blood supply, the drugs aim to slow tumor growth and spread. In mesothelioma, the most established example is bevacizumab (Avastin), used together with chemotherapy.

Origin

VEGF was identified in the 1980s by researchers including Napoleone Ferrara at Genentech, who later developed bevacizumab, the first anti-VEGF antibody approved for cancer (2004). The strategy grew out of Judah Folkman's 1971 hypothesis that tumors depend on angiogenesis, the growth of new blood vessels, and that blocking it could starve cancers.

Significance in Asbestos Context

For patients with pleural mesothelioma, the MAPS trial (2016) showed that adding bevacizumab to standard cisplatin–pemetrexed chemotherapy modestly extended survival, making it a recognized first-line option in eligible patients. Not everyone is a candidate: bevacizumab can raise the risk of bleeding, blood clots, high blood pressure, and problems with wound healing, so patients with certain heart, vascular, or bleeding histories may be excluded. Whether you received, were offered, or were denied VEGF-targeted therapy is part of your medical record and may be relevant when documenting the full course and cost of treatment in a legal claim.

Example Sentence

"After reviewing her heart and bleeding history, the oncologist added a VEGF inhibitor to her chemotherapy regimen for pleural mesothelioma."

Related Terms

Bevacizumab, Angiogenesis, Pemetrexed, Targeted Therapy, Mesothelioma, Immunotherapy

Notes

• Ask your oncologist specifically whether bevacizumab plus cisplatin and pemetrexed is appropriate for you, and if not, why. This is a documented first-line option for many pleural mesothelioma patients.
• Report symptoms like nosebleeds, blood in urine or stool, severe headache, chest pain, leg swelling, or uncontrolled blood pressure promptly; these can signal known VEGF inhibitor side effects.
• If you have upcoming surgery (including biopsies, port placement, or dental procedures), tell your care team. Bevacizumab generally must be paused weeks before and after surgery to allow proper healing.
• Keep copies of infusion records, drug names, dates, and any treatment denials by insurance; these documents matter for both medical continuity and any legal claim related to treatment costs.